Novo Nordisk's Wegovy Pill Faces Its DKK 4.6 Billion Test in Q3 Results

Novo Nordisk reports its nine-month 2026 results today, and the headline figures will not be the most interesting numbers in the release. The number that matters is a single product line: revenue from the oral Wegovy pill, the tablet form of semaglutide that the Danish drugmaker launched in the United States in early January. Analysts expect it to reach DKK 4.6 billion for the third quarter, and whether it clears that bar will say more about Novo's future than any other line in the accounts.

The pill is carrying an unusual burden. It has to grow fast enough to offset decline almost everywhere else in the portfolio. Consensus expects injectable Wegovy to fall 2.1% year on year to DKK 19.9 billion, squeezed by competition from Eli Lilly's Zepbound and softer US prices, and Ozempic to drop 13.7% to DKK 26.5 billion. Total net sales are expected at DKK 73.25 billion, down 2.3% on the year, with adjusted operating profit of DKK 28.35 billion. The pill is the one line pointed in the right direction, and the whole investment case for Novo's transition from injections to tablets rests on it continuing to point that way.

The case for clearing the bar rests on geography. In the second quarter the pill contributed DKK 3.14 billion, mostly from the United States, where Novo reported more than five million prescriptions in roughly 30 weeks and a roughly 90% share of the oral obesity market. Since then the map has widened: the United Kingdom launched in early July, with about 300,000 patients starting within three weeks, Germany followed in late September, and the pill is now officially available in nine countries including France and Spain, with Mexico due this month and Australia targeted by Christmas. A third quarter that adds a full quarter of British sales and a first German contribution to a still-ramping American base has a reasonable path from 3.14 to 4.6 billion.

The case against is price. The US market that built the pill is also the market squeezing it: Medicaid coverage cuts, intensifying competition, and list-price cuts of around 50% for Wegovy scheduled from 1 January 2027 all weigh on what each prescription is worth, even as volumes grow. Not every analyst is convinced the volume story wins: Sydbank projects pill sales of just DKK 4.25 billion for the quarter, while Citi expects DKK 5.3 billion. That spread, more than a billion kroner wide, is the honest measure of how uncertain this number is. Options traders, for their part, are pricing a move of about 7.4% in Novo's shares around the report, which tells you how much is riding on a single morning's figures.

There is a second question in the release, quieter but nearly as telling: what happens to guidance. Novo currently expects adjusted sales and operating profit to land between flat and down 6% at constant exchange rates for the full year, a range it raised after the second quarter. Jyske Bank expects the company to tighten the floor of that range, to a decline of no more than 3% on sales and 4% on operating profit, and JPMorgan expects a strong quarter driven by the pill beating estimates, with guidance raised again. A company that narrows its range upward is telling you the worst case is off the table; one that leaves it alone is telling you it is not sure yet.

My call is that the pill clears the bar, but only just. The launch cadence — a full British quarter, a German opening, an American base still adding prescriptions — points to a number at or above consensus, and JPMorgan's read of a strong quarter leans the same way. But the spread between Sydbank and Citi is a warning against confidence: price pressure in the US is real, and a miss would mean the tablet transition is running slower than the story requires. This is a coin flip with a slight lean, and the print this afternoon will settle it either way. What it will not do is settle the longer question, which is whether a pill can carry a company whose older products are all shrinking at once. That answer takes more than one quarter.